UCB (OTCMKTS:UCBJF) Shares Gap Up - Time to Buy?

Key Points

• UCB SA's share price increased from $241.83 to $251.19, indicating a positive market opening and interest in the stock.
• Morgan Stanley has reiterated an "overweight" rating on UCB's shares, with an overall average rating of "Buy" from analysts.
• The company boasts a debt-to-equity ratio of 0.33 and has been focused on developing products for neurology and immunology diseases.

UCB SA (OTCMKTS:UCBJF - Get Free Report)'s share price gapped up before the market opened on Friday . The stock had previously closed at $241.83, but opened at $251.19. UCB shares last traded at $251.19, with a volume of 32 shares changing hands.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley reiterated an "overweight" rating on shares of UCB in a research note on Monday. One analyst has rated the stock with a Buy rating, According to MarketBeat, the stock has an average rating of "Buy".

UCB Price Performance

The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19. The company has a 50 day moving average price of $222.34 and a 200 day moving average price of $192.76.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.